Home
About UsCommitted to developing a new generation of medicines that go beyond the current standard of care
VistaGen Therapeutics is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of people around the world.
Our VisionStriving for a world no longer gripped by anxiety, fear and depression
VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.
Large Unmet Mental Health Care Needs in Anxiety and Depression
23.7 Million1
Americans suffer from Social Anxiety Disorder
19.4 Million2
Adults in the US had at least one major Depressive Episode
264 Million3
People World-wide suffer from Depression
1. Kantar Health. September 2020. NATIONAL HEALTH AND WELLNESS SURVEY, 2020. [US]. Malvern, PA | 2. Substance Abuse and Mental Health Services Administration, 2020 | 3. World Health Organization
Pipeline VistaGen Products in Development
For Anxiety Disorders
PH94B is an innovative, odorless, rapid-onset CNS pherine nasal spray with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with currently prescribed products.
For Depression
PH10 is an investigational CNS pherine nasal spray with potential to be a fast -acting stand-alone treatment for neuropsychiatric indications involving depression.
For CNS Diseases & Disorders
AV-101 (4-Cl-KYN) is an investigational prodrug designed to be orally administered and to target the NMDA receptor that can be associated with numerous CNS diseases and disorders.
Data as of May 24, 2022 | 4:50 PM EDT